1. Home
  2. Directory
  3. Tennessee
  4. Nashville
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1609071349

DR. ALAN TAN M.D.
Prescription History 1609071349
Internal Medicine - Hematology & Oncology in Nashville, TN

NPI Status: Active since June 20, 2007

Contact Information

3601 THE VANDERBILT CLINIC
NASHVILLE, TN
ZIP 37232
Phone: (615) 322-5000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ALAN TAN M.D., an active Hematology & Oncology specialist practicing in Nashville, TN. Our medical registry currently tracks 9 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 342 documented patient claims. Among these therapy options, the most frequently utilized medication is Prednisone, which accounts for 110 claims alone.

Medication Index

Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 50
30-Day Fills 50.0
Days Supply 1,470
TN State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills40.4
Peer Average Days Supply1,209
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $84,282.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,685.65

State Avg Cost Per Claim

$3,724.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Braftovi

Generic Formulation: EncorafenibSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
TN State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.4
Peer Average Days Supply549
Conservative Utilization

This provider writes prescriptions for this formulation 27.8% less frequently than the standard regional baseline metric for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $208,303.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,023.32

State Avg Cost Per Claim

$14,967.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Encorafenib is used to treat certain types of cancer (such as melanoma skin cancer, cancer in the colon or rectum). Encorafenib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Cabometyx

Generic Formulation: Cabozantinib S-MalateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 637
TN State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.4
Peer Average Days Supply688
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $593,176.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$26,962.58

State Avg Cost Per Claim

$23,575.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat various types of cancer (including kidney, thyroid, liver cancer). Cabozantinib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Erleada

Generic Formulation: ApalutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 637
TN State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills42.3
Peer Average Days Supply1,268
Conservative Utilization

This provider writes prescriptions for this formulation 41.5% less frequently than the standard regional baseline metric for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $338,829.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,117.91

State Avg Cost Per Claim

$14,547.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apalutamide is used to treat men with prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Nubeqa

Generic Formulation: DarolutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
TN State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills45.7
Peer Average Days Supply1,372
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.0% less volume than the regional standard for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $269,177.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,954.31

State Avg Cost Per Claim

$12,936.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Darolutamide is used to treat a certain type of prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 270
TN State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.9
Peer Average Days Supply107
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $235.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.20

State Avg Cost Per Claim

$6.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Orgovyx

Generic Formulation: RelugolixSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 70
30-Day Fills 70.0
Days Supply 2,090
TN State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills54.3
Peer Average Days Supply1,627
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 32.1% more claims than the standard regional baseline profile for TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $227,906.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,255.81

State Avg Cost Per Claim

$2,665.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Relugolix is used to treat prostate cancer in men. It is not a cure. Most types of prostate cancer need the male hormone testosterone to grow and spread. Relugolix works by reducing the amount of testosterone that the body makes. This helps slow or stop the growth of cancer cells.

Prednisone

Generic Formulation: PrednisoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 110
30-Day Fills 116.0
Days Supply 3,423
TN State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills66.3
Peer Average Days Supply1,176
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 103.7% higher than the standard regional baseline profile for TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $469.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.27

State Avg Cost Per Claim

$7.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
TN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills34.3
Peer Average Days Supply1,026
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.8% less volume than the regional standard for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $205,575.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,683.94

State Avg Cost Per Claim

$13,383.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ALAN TAN M.D. provides transparency into local medical care patterns within Nashville, TN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.